Pherecydes Appoints CEO
This article was originally published in Scrip
Pherecydes Pharma, a biotech developing anti-infective therapies based on lytic bacteriophages, has appointed Guy-Charles Fanneau de La Horie CEO. Fanneau de La Horie brings more than 20 years' experience to Pherecydes and has previously held various management roles including positions within Schering-Plough, Biogen and IDM. Recently he was CEO of PathoQuest and previously he held the same position at Neovacs. Prior to this, he was at Biogen where he set up and ran the subsidiaries in France and Benelux.